Mitsubishi Chemical <4188> continues to rise. SMBC Nikko Securities has upgraded their investment rating from "2" to "1", and also raised their target stock price from 960 yen to 1000 yen. It is speculated that they expect the improvement and growth of performance to be achieved through prompt management decisions, judging that the stock price decline since the announcement of the President's succession is excessive. In the short term, better-than-planned performance is expected, mainly with the MMA and ALS therapy drug Rajikavu. In addition, for specialty materials, there is a possibility that performance will significantly improve through selection and concentration.